FDA OKs Subcutaneous Therapy for CIDP

HyQvia, which combines immunoglobulin with hyaluronidase, is administered subcutaneously by a healthcare professional or the patient or caregiver, after appropriate training.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-subcutaneous-therapy-chronic-inflammatory-2024a100015r?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension